[ad_1]
-
The study examined the impact of the Oncotype DX test on 74 patients who used it to determine the course of treatment.
The review examines the activity of a group of 21 genes in the tumor and can help determine more information about cancer, allowing the doctor to know if chemotherapy will benefit from chemotherapy as part of his treatment.
The results of the study on a group of Irish patients will be presented at the annual congress of the European Society. for medical oncology in Munich, Germany.
The test is currently available for private patients. It is free for women in public hospitals whose early stage bad cancer has not spread to the lymph nodes.
This study was extended to patients whose cancer has spread to the lymph nodes.
Research conducted on 74 patients revealed that the test resulted in a 27% reduction in the chemotherapy recommendation from 68 to 48 women.
The recommendation was based on the badysis that women had a low risk of tumor recurrence and tumors that were relatively resistant to chemotherapy. 19659005] The study was led by Dr. Patrick Morris, consulting oncologist at Beaumont Hospital in Dublin, and sponsored by Cancer Trials Ireland.
Ongoing research is examining whether this test can be used in patients before surgery for bad cancer. "
Irish Independent
[ad_2]
Source link
Tags breast cancer chemo spared Test women
